U.S. Active Pharmaceutical Ingredient CDMO Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Application (Oncology, Glaucoma), By Workflow, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Value chain based analysis (Model 2)
                        1.7.3. Multivariate Analysis (Model 3)
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Ancillary Market Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Impact Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. Technological Landscape
                    3.4. Pricing Model Analysis
                    3.5. Regulatory Framework
                    3.6. Supply Chain Analysis
                    3.7. Tariff Impact Analysis
                    3.8. Market Analysis Tools
                        3.8.1. Porter’s Five Forces Analysis
                        3.8.2. PESTEL by SWOT Analysis
Chapter 4. U.S. Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
                    4.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
                    4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
                        4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
                    4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
                        4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. Biologics
                        4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Active Pharmaceutical Ingredient CDMO Market Synthesis Movement Analysis
                    5.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Million)
                    5.4. Synthetic
                        5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Biotech
                        5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
                    6.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
                    6.4. Innovative
                        6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.5. Generics
                        6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. U.S. Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
                    7.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
                    7.4. Oncology
                        7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Hormonal
                        7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.6. Glaucoma
                        7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.7. Cardiovascular disease
                        7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.8. Diabetes
                        7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.9. Others
                        7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. U.S. Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis
                    8.1. Segment Dashboard
                    8.2. U.S. Active Pharmaceutical Ingredient CDMO Market Workflow Movement Analysis
                    8.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
                    8.4. Clinical
                        8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    8.5. Commercial
                        8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Company Categorization
                        9.1.1. Market Leaders
                        9.1.2. Emerging Players
                    9.2. Company Market Share/Assessment Analysis, 2024
                    9.3. Company Profiles
                        9.3.1. Cambrex Corporation
                            9.3.1.1. Company Overview
                            9.3.1.2. Financial Performance
                            9.3.1.3. Product/Service Benchmarking
                            9.3.1.4. Strategic Initiatives
                        9.3.2. Recipharm AB
                            9.3.2.1. Company Overview
                            9.3.2.2. Financial Performance
                            9.3.2.3. Product/Service Benchmarking
                            9.3.2.4. Strategic Initiatives
                        9.3.3. Thermo Fisher Scientific Inc.
                            9.3.3.1. Company Overview
                            9.3.3.2. Financial Performance
                            9.3.3.3. Product/Service Benchmarking
                            9.3.3.4. Strategic Initiatives
                        9.3.4. CordenPharma International
                            9.3.4.1. Company Overview
                            9.3.4.2. Financial Performance
                            9.3.4.3. Product/Service Benchmarking
                            9.3.4.4. Strategic Initiatives
                        9.3.5. Samsung Biologics
                            9.3.5.1. Company Overview
                            9.3.5.2. Financial Performance
                            9.3.5.3. Product/Service Benchmarking
                            9.3.5.4. Strategic Initiatives
                        9.3.6. Lonza
                            9.3.6.1. Company Overview
                            9.3.6.2. Financial Performance
                            9.3.6.3. Product/Service Benchmarking
                            9.3.6.4. Strategic Initiatives
                        9.3.7. Catalent, Inc.
                            9.3.7.1. Company Overview
                            9.3.7.2. Financial Performance
                            9.3.7.3. Product/Service Benchmarking
                            9.3.7.4. Strategic Initiatives
                        9.3.8. Siegfried Holding AG
                            9.3.8.1. Company Overview
                            9.3.8.2. Financial Performance
                            9.3.8.3. Product/Service Benchmarking
                            9.3.8.4. Strategic Initiatives
                        9.3.9. Piramal Pharma Solutions
                            9.3.9.1. Company Overview
                            9.3.9.2. Financial Performance
                            9.3.9.3. Product/Service Benchmarking
                            9.3.9.4. Strategic Initiatives
                        9.3.10. Boehringer Ingelheim International GmbH
                            9.3.10.1. Company Overview
                            9.3.10.2. Financial Performance
                            9.3.10.3. Product/Service Benchmarking
                            9.3.10.4. Strategic Initiatives

List of Tables

Table 1 List of abbreviation
Table 2 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
Table 3 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
Table 4 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drugs, 2021 - 2033 (USD Million)
Table 5 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
Table 6 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 US Active Pharmaceutical Ingredient CDMO Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Segment snapshot
Fig. 15 Competitive landscape snapshot
Fig. 16 Parent market outlook, 2024 (USD Million)
Fig. 17 Ancillary market outlook, 2024 (USD Million)
Fig. 18 US Active Pharmaceutical Ingredient CDMO Market dynamics
Fig. 19 Total R&D drug pipeline size, 2021-2024
Fig. 20 Total drug pipeline by development phase, 2024
Fig. 21 Porter’s five forces analysis
Fig. 22 PESTEL analysis
Fig. 23 US Active Pharmaceutical Ingredient CDMO Market Product outlook: Segment dashboard
Fig. 24 US Active Pharmaceutical Ingredient CDMO Market, by Product segment: Market share, 2025 & 2033
Fig. 25 Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Biologics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 US Active Pharmaceutical Ingredient CDMO Market Synthesis outlook: Segment dashboard
Fig. 30 Active Pharmaceutical Ingredient CDMO Market, by Synthesis segment: Market share, 2025 & 2033
Fig. 31 Synthetic market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Biotech market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 US Active Pharmaceutical Ingredient CDMO Market Drug outlook: Segment dashboard
Fig. 34 Active Pharmaceutical Ingredient CDMO Market, by Drug segment: Market share, 2025 & 2033
Fig. 35 Innovative market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Generics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 US Active Pharmaceutical Ingredient CDMO Market Application outlook: Segment dashboard
Fig. 38 Active Pharmaceutical Ingredient CDMO Market, by Application segment: Market share, 2025 & 2033
Fig. 39 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Hormonal market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Glaucoma market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Cardiovascular disease market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 US Active Pharmaceutical Ingredient CDMO Market Workflow outlook: Segment dashboard
Fig. 46 Active Pharmaceutical Ingredient CDMO Market, by Workflow segment: Market share, 2025 & 2033
Fig. 47 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 Market participant categorization
Fig. 50 Heat map analysis